Compare ARK Genomic Revolution ETF (ARKG) vs McCormick & Company, Incorporated (MKC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Genomic Revolution ETF vs McCormick & Company, Incorporated — how do they compare? ARK Genomic Revolution ETF trades at $44.31, while McCormick & Company, Incorporated trades at $52.75 (market cap $14.27B). The key difference: McCormick & Company, Incorporated pays a 3.61% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, McCormick & Company, Incorporated nearer its low. Which is the better fit depends on your goals.
| ARKG | MKC | |
|---|---|---|
Sector | Sector/Thematic | Consumer Staples |
52-Week High | $44.55 | $72.26 |
52-Week Low | $24.02 | $45.60 |
Market Cap | — | $14.27B |
Enterprise Value | — | $18.87B |
Dividend Yield | — | 3.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG, the ARK Genomic Revolution ETF, trades at $43.04, up 6.06% in the past 24 hours, with a bullish technical signal from moving averages and ADX indicators. The ETF focuses on small- and mid-cap biotech stocks, with its top 10 holdings comprising 59% of the portfolio and a long-term EPS growth rate of 10.7%. Recent news highlights its recovery from a 15% correction, with support emerging at key levels.
The outlook for ARKG is positive, driven by biotech sector tailwinds including a friendlier FDA, strong M&A activity, and AI-driven drug discovery. Risks include high concentration in volatile biotech names and sensitivity to broader market sell-offs. Investors should weigh the growth potential against the inherent volatility of genomics investments.
MKC trades at $52.96, up 1.3% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $59.67 suggesting 13% upside. The company reported Q2 2026 results that beat expectations, driven by the McCormick de Mexico acquisition and margin expansion, with revenue growth of 16.7% year-over-year. The pending $65 billion merger with Unilever's food business represents a transformative opportunity, though integration risks remain.
The outlook is positive, supported by strong profitability metrics, including a 21.91% net income margin and 25.7% ROE, alongside a reasonable valuation with a P/E of 8.81. Key risks include execution of the Unilever deal, competitive pressures in the consumer segment, and potential macroeconomic headwinds affecting consumer spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About McCormick & Company, Incorporated
In its 130-year history, McCormick has grown to become the leading global manufacturer, marketer, and distributor of spices, herbs, extracts, seasonings, and other flavorings. Beyond end consumers, McCormick's customer base also includes top quick-service restaurants, retail grocery chains, and other packaged food and beverage manufacturers, with about 30% of sales generated beyond its home turf to include 150 other countries and territories. In addition to its namesake brand, the firm's portfolio includes Old Bay, Zatarain's, Thai Kitchen, Frank's RedHot, French's, and the recently acquired Cholula brand.
Read more on MKC →
